Army taps Vermillion for ovarian cancer Dx study

04/18/2013 | GenomeWeb Daily News (free registration)

The U.S. Army Medical Research and Materiel Command awarded Vermillion a contract to investigate the cost-benefits profile of the company's OVA1 test for ovarian cancer. The company will examine the assay's clinical use in managed care environments, and a multicenter clinical trial will evaluate the test as a presurgical standard of care in women who have pelvic masses.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY